Replies to post #267692 on Avid Bioservices Inc (CDMO)

[BCS Paladin]

Who will it be

CALICO

[biopharm]

Great Job on the quarterly results Steve, though I was wondering if you could shed some light on the patent for a medical device that was with Allergan... Brigitte Phah, Skywork Solutions... Donald Bollella and with Peregrine Pharmaceuticals... Ramon Valencia ?

Great Job on the quarterly results Steve, though one more question I had was if your company has had any talks or collaborations with any Agricultural use with your patents regarding PS Targeting? ... since it is known that Monsanto, Bayer, Koch and other chemical companies/fertilizers destroy cells within plants just as chemo has done and may also need help in restoring the immune system of plants/crops of our food supply.

Great Job on the quarterly results Steve, though one last question... when you changed transfer agents over to Broadridge, how often do you analyze your shareholder base and can you break down percentage-wise and number of the broker non-votes that exist overseas and what would their average holdings be ?

Lets go analysts... be creative today in asking some questions and don't be timid

[biopharm]

That new medical device ( re: Brigitte Phan/Donald Bollella / Ramon Valencia) probably has the new BP player for Peregrine every so anxious to stryker a deal

Interesting.... more ex-Stryker heading into Peregrine

Lets go Brigitte Phan.... you have been floating around the PAV lists of Peregrine for many years and a little intangible that tells me something big coming from that corner of medical devices

[biopharm]

That new medical device ( re: Brigitte Phan/Donald Bollella / Ramon Valencia) probably has the new BP player for Peregrine every so anxious to stryker a deal

Many eyes and ears on the ground near Stryker in malvern, PA ... because looks like some interesting names begin to apear and all focused on PS Targeting so which way will PS Targeting move towards

Stryker Ortho Biologics to Fujirebio Diagnostics to 300 Technology Drive (Gerald Finkens reward) to 200 Great Valley Parkway (Janssen ex-Centocor) and I'd rather just see J.Carl Barrett of AstraZeneca reveal what PS Targeting biomarkers are all about in Feb but we may hear some surprises before then

http://www.mnmconferences.com/The-Biomarker-Conference#Speakers

---------------------------------------------------------

So much on the line for Big Pharmas and I suspect one of them will make a move, just knowing that the MOA of many protein pathways will prove PS Targeting is the #1 priority

Phosphatidylserine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential.